Posted by Michael Wonder on 28 Sep 2017
Canadian regulator orders price cut of expensive U.S. drug Soliris
27 September 2017 - The maker of the one of the world's most expensive drugs has been ordered to slash the price of the medication in Canada and pay back millions of dollars in revenue that the country's drug-pricing regulator has deemed "excessive."
In a landmark decision released Wednesday, a panel of the Patented Medicine Prices Review Board (PMPRB) ruled that Connecticut-based Alexion Pharmaceuticals Inc. charged more for a rare-disease treatment called Soliris than Canadian law allows.
The decision followed a rare public hearing earlier this year on allegations of excessive pricing of a drug in Canada.
